Custom crystal tombstone marking the acquisition by Mars of veterinary care provider AniCura; and also commemorating the acquisition of veterinary services group Linnaeus.
(8LJW152)
Custom crystal tombstone marking the acquisition by Mars of veterinary care provider AniCura; and also commemorating the acquisition of veterinary services group Linnaeus.
(8LJW152)Pill-themed tombstone commemorating two transactions in the Australian pharmaceutical sector.
(5SSC765)Lucite commemorative marking the research, development, and commercialization agreement between Sanofi and Regenereon. The pharmaceutical firms will focus on antibody cancer treatment s in the field of immuno-oncology.
(5ALR849)Custom crystal tombstone celebrating a second close of Series A financing for Fusion Pharmaceuticals. The Hamilton, Ontario-based firm is focused on radiotherapeutics for treating cancer.
(8ALJ479)Crystal tombstone commemorating an exclusive licensing agreement between Ovid Therapuetics and Angelini Pharma. The agreement centers on the development, manufacturing, and commercialization of a potential treatment for Angelman syndrome.
(20AJH130)Lucite deal tombstone commemorating an agreement for global rights to gout treatment drug ARO-XDH. The agreement was reached between Dublin, Ireland-based Horizon Therapeutics and Arrowhead Pharmaceuticals, headquartered in Pasadena, California.
(21ALJ356)Lucite deal toy marking the acquisition of Prisym ID, a Massachusetts-based company specializing in labeling for clinical trials, medical devices, and pharmaceuticals. The acquirer, Loftware, is the largest global software firm focused on enterprise labeling and artwork management.
(22AKL039)Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR’s therapy for PBC, a rare autoimmune disease affecting the liver.
(22ALJ081)
